B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier:
NCT01028430
First received: December 8, 2009
Last updated: February 5, 2013
Last verified: February 2013

December 8, 2009
February 5, 2013
July 1998
January 2014   (final data collection date for primary outcome measure)
expression of cell surface antigens HLA-DR and CD38+ markers in B-CLL cells compared to normal B-lymphocytes [ Time Frame: samples will be taken at the beginning, week 2, 4,6,8,12,and 24 (for blood), and bone marrow samples at weeks 2 and 6. ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT01028430 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging
B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging

B-CLL is the most prevalent leukemia in the Western hemisphere, accounting for ~25% of all leukemia's (1). This disease occurs virtually exclusively in the aging population, with the median age of diagnosis ranging between the mid 60s and the early 70s. Indeed, its occurrence before the age of 50 is quite unusual. This increase in occurrence with age is not unique to B-CLL; rather, it is characteristic several B cell lymphoproliferative disorders (e.g., non-Hodgkin's lymphoma, multiple myeloma). Gender and race also influence the development of B-CLL. Thus, the ratio of men: women is ~2:1 and the prevalence is increased in Caucasians. The rate of occurrence of B-CLL among Asians is significantly lower than for Caucasians and this does not increase with immigration to the West. DNA sequence analyses performed in our laboratory and in those of others indicate that B-CLL cells from unrelated patients share Ig V gene characteristics. These include the use of selected genes, the association of these genes with certain D and JH gene segments that code for unique CDR3 motifs, and the occasional occurrence of highly similar VHDJH + VLJL pairs. In ~50% cases, these rearranged genes are mutated, whereas in the others mutations are infrequent; this difference is related to the VH gene family used by the B-CLL cell.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided

Blood cells, tissue

Non-Probability Sample

Chronic Lymphocytic Leukemia Community Sample

Chronic Lymphocytic Leukemia
Not Provided
Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
1000
January 2014
January 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18 years of age Patients must be willing to be contacted in the future

Exclusion Criteria:

  • Patients who are known to be anemic, with a hemoglobin <8 PAtients who are known to be infected with HIV
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01028430
04-046
No
North Shore Long Island Jewish Health System
North Shore Long Island Jewish Health System
Not Provided
Principal Investigator: Nicholas Chiorazzi, MD North Shore-LIJ Health System
North Shore Long Island Jewish Health System
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP